Morgan Stanley analyst Michael Ulz raised the firm’s price target on Vir Biotechnology (VIR) to $24 from $20 and keeps an Overweight rating on the shares. Phase 1 VIR-5500 data confirm its “potential best-in-class profile in prostate cancer,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR: